• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Comparison between two labeled agents in mice using a coinjection-ratio approach in contrast to a conventional group approach.使用共注射比法而非传统分组法在小鼠中比较两种标记物。
Nucl Med Biol. 2014 Jan;41(1):127-31. doi: 10.1016/j.nucmedbio.2013.10.001. Epub 2013 Oct 9.
2
Further investigations of morpholino pretargeting in mice--establishing quantitative relations in tumor.小鼠中吗啉代预靶向的进一步研究——建立肿瘤中的定量关系
Eur J Nucl Med Mol Imaging. 2005 Sep;32(9):1115-23. doi: 10.1007/s00259-005-1853-5.
3
Synthesis and in vitro characterization of a dendrimer-MORF conjugate for amplification pretargeting.用于扩增预靶向的树枝状聚合物 - MORF 共轭物的合成及体外表征
Bioconjug Chem. 2008 Aug;19(8):1518-25. doi: 10.1021/bc8001024. Epub 2008 Jul 23.
4
Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF.使用MORF-B72.3抗体和放射性标记的cMORF对小鼠体内的CWR22前列腺肿瘤进行预靶向。
Eur J Nucl Med Mol Imaging. 2008 Feb;35(2):272-80. doi: 10.1007/s00259-007-0606-z. Epub 2007 Oct 2.
5
Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice.预测放射性标记的cMORF效应物在MORF预靶向小鼠体内的生物分布。
Eur J Nucl Med Mol Imaging. 2007 Feb;34(2):237-46. doi: 10.1007/s00259-006-0222-3.
6
Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector.使用与MORF偶联的CC49抗体和放射性标记的互补cMORF效应物在小鼠中进行肿瘤预靶向。
Q J Nucl Med Mol Imaging. 2010 Jun;54(3):333-40. Epub 2009 Dec 15.
7
90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy.90Y 标记的磷酰胺二酯吗啉寡聚物用于前靶向放射治疗。
Bioconjug Chem. 2011 Dec 21;22(12):2539-45. doi: 10.1021/bc200366t. Epub 2011 Nov 3.
8
Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake.用放射性标记的吗啉代寡聚物在荷瘤小鼠中进行预靶向,显示肾脏摄取率低。
Eur J Nucl Med Mol Imaging. 2004 Mar;31(3):417-24. doi: 10.1007/s00259-003-1393-9. Epub 2003 Dec 23.
9
Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept.扩增靶向:一种经过改良的预靶向方法,具有信号放大的潜力——概念验证。
J Nucl Med. 2004 Jun;45(6):1087-95.
10
A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49.使用 MORF/cMORF 预靶向和抗 TAG-72 抗体 CC49 进行临床前 188Re 肿瘤治疗研究。
Cancer Biol Ther. 2010 Oct 15;10(8):767-74. doi: 10.4161/cbt.10.8.12879.

引用本文的文献

1
A Revisit to the Pretargeting Concept-A Target Conversion.重新审视预靶向概念——一种靶点转换
Front Pharmacol. 2018 Dec 17;9:1476. doi: 10.3389/fphar.2018.01476. eCollection 2018.

本文引用的文献

1
Rules of thumb for maximum percent tumor accumulation.肿瘤最大累积百分比的经验法则。
Nucl Med Biol. 2013 Aug;40(6):865-7. doi: 10.1016/j.nucmedbio.2013.04.010. Epub 2013 Jun 18.
2
90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy.90Y 标记的磷酰胺二酯吗啉寡聚物用于前靶向放射治疗。
Bioconjug Chem. 2011 Dec 21;22(12):2539-45. doi: 10.1021/bc200366t. Epub 2011 Nov 3.
3
A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49.使用 MORF/cMORF 预靶向和抗 TAG-72 抗体 CC49 进行临床前 188Re 肿瘤治疗研究。
Cancer Biol Ther. 2010 Oct 15;10(8):767-74. doi: 10.4161/cbt.10.8.12879.
4
Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector.使用与MORF偶联的CC49抗体和放射性标记的互补cMORF效应物在小鼠中进行肿瘤预靶向。
Q J Nucl Med Mol Imaging. 2010 Jun;54(3):333-40. Epub 2009 Dec 15.
5
The ratio of maximum percent tumour accumulations of the pretargeting agent and the radiolabelled effector is independent of tumour size.靶向前体药物与放射性效应物的最大肿瘤累积百分比比值与肿瘤大小无关。
Eur J Cancer. 2009 Nov;45(17):3098-103. doi: 10.1016/j.ejca.2009.09.007. Epub 2009 Oct 5.
6
Replacing 99mTc with 111In improves MORF/cMORF pretargeting by reducing intestinal accumulation.用111铟取代99锝可通过减少肠道蓄积来改善MORF/cMORF预靶向。
Mol Imaging Biol. 2009 Sep-Oct;11(5):303-7. doi: 10.1007/s11307-009-0209-0. Epub 2009 Mar 27.
7
A semiempirical model of tumor pretargeting.肿瘤预靶向的半经验模型。
Bioconjug Chem. 2008 Nov 19;19(11):2095-104. doi: 10.1021/bc8002748.
8
A new TAG-72 cancer marker peptide identified by phage display.通过噬菌体展示鉴定出的一种新型TAG-72癌症标志物肽。
Cancer Lett. 2008 Dec 8;272(1):122-32. doi: 10.1016/j.canlet.2008.07.009. Epub 2008 Aug 23.
9
Further discussions on choosing the number of animals for an experiment.关于实验动物数量选择的进一步讨论。
Nucl Med Biol. 2008 Jan;35(1):1-2. doi: 10.1016/j.nucmedbio.2007.10.002.
10
An improved method for covalently conjugating morpholino oligomers to antitumor antibodies.一种将吗啉代寡聚物与抗肿瘤抗体共价偶联的改进方法。
Bioconjug Chem. 2007 May-Jun;18(3):983-8. doi: 10.1021/bc060208v. Epub 2007 Mar 27.

使用共注射比法而非传统分组法在小鼠中比较两种标记物。

Comparison between two labeled agents in mice using a coinjection-ratio approach in contrast to a conventional group approach.

机构信息

Department of Radiology, University of Massachusetts Medical School, Worcester, MA 01655.

出版信息

Nucl Med Biol. 2014 Jan;41(1):127-31. doi: 10.1016/j.nucmedbio.2013.10.001. Epub 2013 Oct 9.

DOI:10.1016/j.nucmedbio.2013.10.001
PMID:24210286
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3855254/
Abstract

INTRODUCTION

The differences between two agents often need to be accurately defined in vivo. Usually they are injected respectively into two groups of subjects. However, if the two agents do not interact with each other in vivo, a coinjection would serve the same purpose. We believe some individual differences in biodistribution may be circumvented through this approach by calculating organ level ratios.

METHODS

A model system of MORF/cMORF pretargeting (MORF/cMORF is a complementary pair of DNA analogues) was employed in connection with an on-going tumor therapeutic project. Human LS174T cells were implanted into the flank of severely immuno-compromised NOD-scid IL2rg(null) mice. The tumor was confirmed to express TAG-72 antigens. At 16 days post tumor inoculation, mice received IV 60 μg of MORF-conjugated CC49 (an antiTAG-72 antibody), followed 2 days later by a low-mass-dose IV coinjection containing 2.5 μg of (90)Y-cMORF and 2.5 μg of (99m)Tc-cMORF. At 3 h post radioactivity injection, the distribution of (99m)Tc was imaged on a SPECT/CT camera and then organs were excised and counted for (90)Y and (99m)Tc. Because the two labeled cMORFs do not react or interact with each other in vivo, the two groups of (90)Y and (99m)Tc data enabled a conventional group comparison. In a new effort, (90)Y/(99m)Tc ratios were calculated. Student's t-test and retrospective power analysis were performed for both approaches. In the new approach, the ratios were set at 1 as the null hypothesis.

RESULTS

The Student's t-test in the conventional group approach indicated that the two labeled cMORFs distributed similarly, but significant differences were observed in salivary gland and large intestines. The coinjection-ratio approach certainly did not subvert the results of the conventional approach but revealed subtler differences. The P values were reduced, the powers were increased in most organs, and more significant differences were observed. The increased sensitivity was due to the reduced CV%s (SD/average*100%) of the (90)Y/(99m)Tc ratios. Therefore, some individual differences were circumvented and notably the ratio approach differentiated individual differences into ratio-correctable and ratio-uncorrectable.

CONCLUSIONS

Although the conventional approach is reliable, the coinjection-ratio approach using organ level ratios is more sensitive and therefore is recommended whenever possible. In addition, it differentiates individual differences into "coinjection correctable" and "coinjection uncorrectable".

摘要

简介

通常情况下,需要在体内准确地定义两种药物之间的差异。通常,它们分别注射到两组受试者中。然而,如果两种药物在体内不相互作用,那么共注射就可以达到同样的目的。我们相信,通过这种方法计算器官水平的比值,可以避免一些个体差异导致的生物分布差异。

方法

我们采用了 MORF/cMORF 预靶向(MORF/cMORF 是一对互补的 DNA 类似物)模型系统,与正在进行的肿瘤治疗项目相关联。将人 LS174T 细胞植入严重免疫缺陷的 NOD-scid IL2rg(null) 小鼠的侧腹。肿瘤被证实表达 TAG-72 抗原。在肿瘤接种后 16 天,小鼠接受 IV 注射 60μg 的 MORF 缀合的 CC49(一种抗 TAG-72 抗体),两天后再注射低质量剂量的 IV 共注射,其中含有 2.5μg 的 (90)Y-cMORF 和 2.5μg 的 (99m)Tc-cMORF。在放射性注射后 3 小时,用 SPECT/CT 相机对 (99m)Tc 的分布进行成像,然后取出器官并计数 (90)Y 和 (99m)Tc。由于两种标记的 cMORF 在体内不反应或相互作用,因此两组 (90)Y 和 (99m)Tc 数据可以进行常规的组间比较。在一项新的研究中,计算了 (90)Y/(99m)Tc 比值。对于这两种方法都进行了学生 t 检验和回顾性功效分析。在新方法中,将 (90)Y/(99m)Tc 比值设定为 1 作为零假设。

结果

常规组方法中的学生 t 检验表明,两种标记的 cMORF 分布相似,但唾液腺和大肠有显著差异。共注射-比值方法肯定没有颠覆常规方法的结果,但揭示了更细微的差异。P 值降低,大多数器官的功效增加,观察到更多显著差异。灵敏度的提高是由于 (90)Y/(99m)Tc 比值的 CV%(SD/平均值*100%)降低。因此,一些个体差异得到了规避,特别是比值方法将个体差异分为比值可纠正和比值不可纠正。

结论

尽管常规方法是可靠的,但使用器官水平比值的共注射-比值方法更敏感,因此只要可能,建议使用该方法。此外,它将个体差异分为“共注射可纠正”和“共注射不可纠正”。